Open AccessReal-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Author(s) -
Neşe Demirtürk,
Bilgehan Aygen,
İ̇lhami Çelik,
Reşit Mıstık,
Sıla Akhan,
Şener Barut,
Onur Ural,
Ayşe Batırel,
Funda Şimşek,
Gülden Ersöz,
Dilara İnan,
Sami Kınıklı,
Nesrin Türker,
Hüseyin Bilgin,
Yunus Gürbüz,
Necla Tülek,
Hüseyin Tarakçı,
Orhan Yıldız,
Emine Türkoğlu,
Deniz Kamalak Güzel,
Sümeyra Şimşek,
Nazan Tuna,
Nazlım Aktuğ Demir,
Atahan Çağatay,
Rıza Aytaç Çeti̇nkaya,
Faruk Karakeçili,
İsmail Necati Hakyemez,
Günay Tuncer Ertem,
Bahar Örmen,
Pınar Korkmaz,
Uluhan Yıldız,
Ziya Kuruüzüm,
Alper Şener,
Selcan Arslan Özel,
Savaş Öztürk,
Kaya Süer,
Mustafa Kemal Çelen,
Petek Konya,
Ali Aşan,
Neşe Saltoğlu,
Nurhan Doğan
Publication year - 2021
Publication title -
the turkish journal of gastroenterology/the turkish journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
pISSN - 1300-4948
DOI - 10.5152/tjg.2020.19569
Subject(s) - medicine , sofosbuvir , ribavirin , discontinuation , ledipasvir , hepatitis c , adverse effect , cirrhosis , hepatitis c virus , demographics , gastroenterology , immunology , virus , demography , sociology
In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice.